| Autor: |
Staci L. Sudenga, B. Nelson Torres, Matthys H. Botha, Michele Zeier, Martha E. Abrahamsen, Richard H. Glashoff, Susan Engelbrecht, Maarten F. Schim Van der Loeff, Louvina E. Van der Laan, Siegfried Kipping, Douglas Taylor, Anna R. Giuliano |
| Jazyk: |
angličtina |
| Rok vydání: |
2017 |
| Předmět: |
|
| Zdroj: |
Papillomavirus Research, Vol 3, Iss , Pp 50-56 (2017) |
| Druh dokumentu: |
article |
| ISSN: |
2405-8521 |
| DOI: |
10.1016/j.pvr.2017.02.001 |
| Popis: |
Background: HPV antibodies are a marker of past exposure to the virus. Our objective was to assess HPV serostatus pre- and post-vaccination among HIV-negative women. Methods: Women aged 16â24 years old were randomized in a placebo controlled trial utilizing the 4-valent HPV (4vHPV) vaccine (NCT01489527, clinicaltrials.gov). Participants (n=389) received the 4vHPV vaccine or placebo following a three dose schedule. Sera were collected at Day 1 and Month 7 for assessment of HPV 6, 11, 16, and 18 neutralizing antibody levels using a multiplex competitive Luminex immunoassay (Merck) based on detecting the L1 capsid antigen for each HPV type. Results: Seroprevalence was 73% for HPV6, 47% for HPV11, 33% for HPV16, and 44% for HPV18. Seroprevalence for any HPV type did not significantly differ by age or lifetime number of partners. The majority of participants (64%) had two or more 4vHPV antibodies present at enrollment and 12% had antibodies to all four. Among women in the vaccine arm, those that were seropositive for HPV16 at enrollment had higher titers at month 7 compared to women that were seronegative for HPV16 at enrollment; this trend holds for the other HPV types as well. Seroconversion among baseline seronegative participants in the placebo group ranged from 5% for HPV16 to 23% for HPV6. Conclusion: HPV seroprevalence was high in this population, emphasizing the need to vaccinate prior to sexual debut. Keywords: HPV vaccine, EVRI, Seroprevalence, cLIA |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
